Meanwhile, immunohistochemistry and ELISA further confirmed that CSBTA significantly reduced RANKL secretion and osteoporosis in the tibial marrow cavity (Figure 3). Taken together, these in vivo results suggested that CSBTA could ameliorate this CIBP and bone lesion by inhibiting breast cancer cell-induced osteoclast formation and function. Here, TNFSF11 is linked to osteoporosis.